Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APHOS3
2024-514837-39-00Phase 3Authorised
- Sponsor
- Rouen University Hospital
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aprepitant in obstructive sleep apnea hypopnea syndrome (OSAHS) and essential hypertension (2 arms), sponsored by Rouen University Hospital. Primary endpoint: 24-hour aldosteronuria. Planned start Jul 2024; status: authorised.
02
Drugs
aprepitant
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)essential hypertension
Beyond the preview
Go deeper on 2024-514837-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514837-39-00.